# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Susquehanna analyst Bascome Majors maintains RXO (NYSE:RXO) with a Negative and raises the price target from $14 to $20.
Jefferies analyst Stephanie Moore maintains RXO (NYSE:RXO) with a Buy and lowers the price target from $33 to $31.
Benchmark analyst Christopher Kuhn reiterates RXO (NYSE:RXO) with a Hold.
Morgan Stanley analyst Ravi Shanker maintains RXO (NYSE:RXO) with a Equal-Weight and raises the price target from $19 to $26.
TD Cowen analyst Jason Seidl maintains RXO (NYSE:RXO) with a Hold and raises the price target from $23 to $28.
JP Morgan analyst Brian Ossenbeck maintains RXO (NYSE:RXO) with a Underweight and raises the price target from $25 to $26.
Oppenheimer analyst Scott Schneeberger maintains RXO (NYSE:RXO) with a Outperform and raises the price target from $22 to $31.
UBS analyst Joseph Parkhill maintains RXO (NYSE:RXO) with a Neutral and raises the price target from $22 to $31.